Ivan Cheung’s post-Eisai life takes hold at NextPoint Therapeutics; Sanofi, Takeda announce CFO exits

Ivan Cheung

Ivan Cheung, who led Eisai’s US business and was a central figure in the biotech’s Alzheimer’s work, has stepped into the CEO position at a Cambridge, MA startup.

He started running immuno-oncology outfit NextPoint Therapeutics last month, having departed Eisai
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Advertisement — Advertise with Biotech Networks